Neurodegenerative Disease Archives - Page 2 of 7 - Xtalks

Wednesday, August 12, 2026 | 11am EDT: Accelerate Cell Culture Media Development with Automated Cell Analysis

MapLight Therapeutics Raises $296M in IPO to Advance CNS Drug Pipeline

October 31, 2025

LB Pharmaceuticals IPO Raises $285M to Advance Late-Stage Neuropsychiatry Pipeline

October 23, 2025

Biomarker Testing Strategies for Enhancing Ultrasensitive Immunoassays

December 10, 2025

Boosting clinical trial success in Alzheimer’s, Parkinson’s and other neurodegenerative diseases

October 22, 2025

Biomarkers in Precision Medicine: Unlocking the Future of Targeted Care

September 23, 2025

p-Tau 205 and p-Tau 212: Emerging Biomarkers for Alzheimer’s Disease Research

September 11, 2025

Progressing Beyond Exploratory Endpoints: The Value of Digital Biomarkers in Neuroscience Clinical Studies

Diagnostics News

Optive AI Gets FDA Clearance, Elevates Image Quality for Swoop Portable MRI

BrainSense Brain Stimulation System from Medtronic Wins FDA Nod for Parkinson’s

February 28, 2025

FDA Greenlights Monthly IV Dosing for Alzheimer’s Med Leqembi

January 29, 2025

BlueRock Advances Bemdaneprocel Cell Therapy to Phase III Trial for Parkinson’s Disease

January 16, 2025

Clinical Trial News

AbbVie’s Tavapadon Reduces Motor Impairments in Phase III Parkinson’s Trial

December 11, 2024

Jupiter Neurosciences Makes Way in CNS Treatments with $11M IPO

December 4, 2024

How GE HealthCare’s SIGNA MAGNUS 3.0T Transforms Neuroimaging

November 13, 2024

Accelerating Alzheimer’s Therapy Innovation: A New Horizon in Blood-Based Biomarkers

November 8, 2024

Diagnostics News

Roche’s Elecsys Amyloid Plasma Panel Blood Test Shows Good Accuracy in Ruling Out Alzheimer’s Disease

November 1, 2024

Next Page »